When placebos outperform CNS drugs – an interesting article on Seeking Alpha.
Afinitor – new cancer blockbuster for Novartis? – Novartis AG’s cancer pill Afinitor, approved yesterday by U.S. regulators, has the potential to generate several billion dollars in annual sales, according to the company’s head of oncology, David Epstein. Afinitor “could be a multi- or mega-blockbuster, in time,” Epstein said in a telephone interview.
Good news for once-weekly Byetta – superior results compared to two existing diabetes treatments.
PLUS: The 5-in-1 “polypill”.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff